


### Claims

1. A compound of the formula:



7      wherein

8           A<sup>1</sup> is a D- or L-isomer of an aromatic amino acid, or is  
9 deleted;

10                   A<sup>2</sup> is a D-isomer selected from the group consisting of  
11                   of Cys, Pen, an aromatic amino acid, or an aliphatic amino  
12                   acid;

13 A<sup>3</sup> is an aromatic amino acid;

14 A<sup>4</sup> is Trp or D-Trp;

15 A<sup>6</sup> is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic  
16 amino acid;

17 A' is Cys, Pen, or an aromatic or an aliphatic amino  
18 acid;

19 A<sup>8</sup> is a D- or L-isomer selected from the group  
20 consisting of Thr, Ser, an aromatic amino acid, or an  
21 aliphatic amino acid;

22           each of R<sub>1</sub> and R<sub>2</sub>, is, independently, H or substituted  
23   or unsubstituted lower alkyl, aryl, aryl lower alkyl,  
24   heterocycle, heterocycle lower alkyl, E<sub>1</sub>SO<sub>2</sub> or E<sub>1</sub>CO (where E<sub>1</sub> is  
25   aryl, aryl lower alkyl, heterocycle, or heterocycle lower  
26   alkyl), where said substituent is halo, lower alkyl, hydroxy,  
27   halo lower alkyl, or hydroxy lower alkyl; and

28                   R<sub>3</sub> is OH, NH<sub>2</sub>, C<sub>1-12</sub> alkoxy, or NH-Y-CH<sub>2</sub>-Z, wherein Y is  
 29   a C<sub>1-12</sub> hydrocarbon moiety and Z is H, OH, CO<sub>2</sub>H, or CONH<sub>2</sub>, or R<sub>3</sub>,  
 30   together with the carbonyl group of A<sup>8</sup> attached thereto, are  
 31   reduced to form H, lower alkyl, or hydroxy lower alkyl;  
 32   provided if A<sup>2</sup> is D-Cys or D-Pen, and A<sup>7</sup> is Cys or Pen, then a  
 33   disulfide bond links the sidechains of A<sup>2</sup> and A<sup>7</sup>, and if A<sup>1</sup> is

34 D-Phe or p-NO<sub>2</sub>-Phe; A<sup>2</sup> is D-Cys; A<sup>3</sup> is Phe or Tyr; A<sup>6</sup> is Thr or  
35 Val; and A<sup>7</sup> is Cys; then A<sup>8</sup> is  $\beta$ -Nal.

1       2. A compound of claim 1, wherein A<sup>2</sup> is D-Cys, A<sup>7</sup> is  
2 Cys, and A<sup>4</sup> is D-Trp.

1       3. A compound of claim 2, wherein A<sup>1</sup> is an L-  
2 aromatic amino acid.

1       4. A compound of claim 3, wherein A<sup>1</sup> and A<sup>3</sup>,  
2 independently, is  $\beta$ -Nal, o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
3 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
4 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
5 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His,  
6 Igl, Tyr(I), Bta, Bip, Npa, or Pal; A<sup>6</sup> is Thr, Ser, Tle,  
7 Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle,  $\beta$ -Ala, Gaba, or Val;  
8 and A<sup>8</sup> is the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, p-X-Phe  
9 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), o-X-Phe  
10 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe  
11 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), Igl,  
12 Tyr(Bzl), or  $\beta$ -Nal.

1       5. A compound of claim 4, wherein A<sup>1</sup> is  $\beta$ -Nal, Npa,  
2 Igl, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN-Phe; A<sup>3</sup> is Tyr,  
3 Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or Leu; A<sup>8</sup> is p-F-  
4 Phe,  $\beta$ -Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R<sub>1</sub> is H,  
5 CH<sub>3</sub>CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-  
6 hydroxyethyl)-1-piperazineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub> is  
7 NH<sub>2</sub>.

1       6. A compound of claim 5, wherein A<sup>3</sup> is Pal.

2       7. A compound of claim 4 of the formula:

3       H<sub>2</sub>- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;

4       (H) (CH<sub>3</sub>CO)- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>

5 (V);

6 (H) - (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) -  $\beta$ -Nal-D-  
7 Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
8 (H) - (4 - (2-hydroxyethyl) - 1-piperazineethanesulfonyl) -  $\beta$ -  
9 Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
10 H<sub>2</sub>- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
11 (H) (CH<sub>3</sub>CO) -  $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
12 (H) - (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) -  $\beta$ -Nal-D-  
13 Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
14 (H) - (4 - (2-hydroxyethyl) - 1-piperazineethanesulfonyl) -  $\beta$ -  
15 Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
16 H<sub>2</sub>- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
17 (H) (CH<sub>3</sub>CO) -  $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
18 (H) (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) -  $\beta$ -Nal-D-  
19 Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
20 (H) (4 - (2-hydroxyethyl) - 1-piperazineethanesulfonyl) -  $\beta$ -  
21 Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
22 H<sub>2</sub>- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
23 (H) (CH<sub>3</sub>CO) -  $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
24 (H) (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) -  $\beta$ -Nal-D-  
25 Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
26 (H) (4 - (2-hydroxyethyl) - 1-piperazineethanesulfonyl) -  $\beta$ -  
27 Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
28 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
29 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
30 (H) (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) - Phe-D-Cys-  
31 Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
32 (H) (4 - (2-hydroxyethyl) - 1-piperazineethanesulfonyl) - Phe-  
33 D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
34 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
35 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
36 (H) (4 - (2-hydroxyethyl) - 1-piperazinylacetyl) - Phe-D-Cys-  
37 Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
38 (H) (4 - (2-hydroxyethyl) - 1-piperazineethanesulfonyl) - Phe-  
39 D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
40 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;

41 (H) (CH<sub>3</sub>CO) - Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
42 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - Phe-D-Cys-  
43 Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
44 (H) (4- (2-hydroxyethyl) -1-piperazineethanesulfonyl) - Phe-  
45 D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
46 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
47 (H) (CH<sub>3</sub>CO) - β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
48 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
49 Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
50 (H) (4- (2-hydroxyethyl) -1-piperazineethanesulfonyl) - β-  
51 Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
52 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
53 (H) (CH<sub>3</sub>CO) - β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
54 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
55 Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
56 (H) (4- (2-hydroxyethyl) -1-piperazineethanesulfonyl) - β-  
57 Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
58 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
59 H (CH<sub>3</sub>CO) - β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
60 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
61 Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
62 (H) (4- (2-hydroxyethyl) -1-piperazineethanesulfonyl) - β-  
63 Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
64 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
65 (H) (CH<sub>3</sub>CO) - β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
66 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - β-Nal-D-  
67 Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
68 (H) (4- (2-hydroxyethyl) -1-piperazineethanesulfonyl) - β-  
69 Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
70 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
71 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
72 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
73 Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;  
74 (H) (4- (2-hydroxyethyl) -1-piperazineethanesulfonyl) Phe-  
75 D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;

76       $H_2$  - Phe - D - Cys - Pal - D - Trp - Lys - Thr - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
77      (H) (CH<sub>3</sub>CO) Phe - D - Cys - Pal - D - Trp - Lys - Thr - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
78      (H) (4 - (2 - hydroxyethyl) - 1 - piperazinylacetyl) Phe - D - Cys -  
79      Pal - D - Trp - Lys - Thr - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
80      (H) (4 - (2 - hydroxyethyl) - 1 - piperazineethanesulfonyl) Phe -  
81      D - Cys - Pal - D - Trp - Lys - Thr - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
82      H<sub>2</sub> - Phe - D - Cys - Tyr - D - Trp - Lys - Thr - Cys - Thr - NH<sub>2</sub>;  
83      (H) (CH<sub>3</sub>CO) Phe - D - Cys - Tyr - D - Trp - Lys - Thr - Cys - Thr - NH<sub>2</sub>;  
84      (H) (4 - (2 - hydroxyethyl) - 1 - piperazinylacetyl) Phe - D - Cys -  
85      Tyr - D - Trp - Lys - Thr - Cys - Thr - NH<sub>2</sub>;  
86      (H) (4 - (2 - hydroxyethyl) - 1 - piperazineethanesulfonyl) Phe -  
87      D - Cys - Tyr - D - Trp - Lys - Thr - Cys - Thr - NH<sub>2</sub>;  
88      H<sub>2</sub> - Phe - D - Cys - Pal - D - Trp - Lys - Thr - Cys - Thr - NH<sub>2</sub>;  
89      (H) (CH<sub>3</sub>CO) - Phe - D - Cys - Pal - D - Trp - Lys - Thr - Cys - Thr - NH<sub>2</sub>;  
90      (H) (4 - (2 - hydroxyethyl) - 1 - piperazinylacetyl) Phe - D - Cys -  
91      Pal - D - Trp - Lys - Thr - Cys - Thr - NH<sub>2</sub>;  
92      (H) (4 - (2 - hydroxyethyl) - 1 - piperazineethanesulfonyl) Phe -  
93      D - Cys - Pal - D - Trp - Lys - Thr - Cys - Thr - NH<sub>2</sub>;  
94      H<sub>2</sub> -  $\beta$  - Nal - D - Cys - Tyr - D - Trp - Lys - Abu - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
95      H<sub>2</sub> - Phe - D - Cys - Tyr - D - Trp - Lys - Abu - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
96      H<sub>2</sub> -  $\beta$  - Nal - D - Cys - Pal - D - Trp - Lys - Abu - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
97      H<sub>2</sub> - Phe - D - Cys - Pal - D - Trp - Lys - Abu - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
98      H<sub>2</sub> -  $\beta$  - Nal - D - Cys - Tyr - D - Trp - Lys - Abu - Cys - Thr - NH<sub>2</sub>;  
99      H<sub>2</sub> - Phe - D - Pen - Tyr - D - Trp - Lys - Val - Pen -  $\beta$  - Nal - NH<sub>2</sub>; or  
100      H<sub>2</sub> - Phe - D - Pen - Pal - D - Trp - Lys - Thr - Pen - Thr - NH<sub>2</sub>;  
101      H<sub>2</sub> - Dip - D - Cys - Pal - D - Trp - Lys - Val - Cys - Dip - NH<sub>2</sub>;  
102      H<sub>2</sub> - F<sub>5</sub> - Phe - D - Cys - His - D - Trp - Lys - Val - Cys - F<sub>5</sub> - Phe - NH<sub>2</sub>;  
103      H<sub>2</sub> - Dip - D - Cys - Pal - D - Trp - Lys - Val - Cys -  $\beta$  - Nal - NH<sub>2</sub>;  
104      H<sub>2</sub> - m - F - Phe - D - Cys - Pal - D - Trp - Lys - Val - Cys - m - F - Phe - NH<sub>2</sub>;  
105      H<sub>2</sub> - o - F - Phe - D - Cys - Pal - D - Trp - Lys - Val - Cys - o - F - Phe - NH<sub>2</sub>;  
106      H<sub>2</sub> - p - F - Phe - D - Cys - Pal - D - Trp - Lys - Val - Cys - p - F - Phe - NH<sub>2</sub>;  
107      H<sub>2</sub> - F<sub>5</sub> - Phe - D - Cys - Pal - D - Trp - Lys - Val - Cys - F<sub>5</sub> - Phe - NH<sub>2</sub>;  
108      H<sub>2</sub> - F<sub>5</sub> - Phe - D - Cys - 2 - Pal - D - Trp - Lys - Val - Cys - F<sub>5</sub> - Phe - NH<sub>2</sub>;  
109      H<sub>2</sub> -  $\beta$  - Nal - D - Cys - His - D - Trp - Lys - Val - Cys - D - Dip - NH<sub>2</sub>;  
110      H<sub>2</sub> - Dip - D - Cys - His - D - Trp - Lys - Val - Cys -  $\beta$  - Nal - NH<sub>2</sub>;

111 H<sub>2</sub>-Dip-D-Cys-His-D-Trp-Lys-Val-Cys-Dip-NH<sub>2</sub>;  
112 H<sub>2</sub>-β-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
113 H<sub>2</sub>-Trp-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH<sub>2</sub>;  
114 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH<sub>2</sub>;  
115 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-p-F-Phe-NH<sub>2</sub>;  
116 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
117 H<sub>2</sub>-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
118 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Nle-Cys-β-Nal-NH<sub>2</sub>;  
119 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Ile-Cys-β-Nal-NH<sub>2</sub>;  
120 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Gly-Cys-β-Nal-NH<sub>2</sub>;  
121 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Ala-Cys-β-Nal-NH<sub>2</sub>;  
122 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Leu-Cys-β-Nal-NH<sub>2</sub>;  
123 H<sub>2</sub>-Bip-D-Cys-Tyr-D-Trp-Lys-Ile-Cys-Bip-NH<sub>2</sub>;  
124 H<sub>2</sub>-p-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-p-F-Phe-NH<sub>2</sub>;  
125 H<sub>2</sub>-Npa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Tyr-NH<sub>2</sub>;  
126 H<sub>2</sub>-m-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-m-F-Phe-NH<sub>2</sub>;  
127 H<sub>2</sub>-o-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-o-F-Phe-NH<sub>2</sub>;  
128 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Dip-NH<sub>2</sub>;  
129 H<sub>2</sub>-Cpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Cpa-NH<sub>2</sub>;  
130 H<sub>2</sub>-Igl-D-Cys-Pal-D-Trp-Lys-Val-Cys-Igl-NH<sub>2</sub>;  
131 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-Dip-NH<sub>2</sub>;  
132 H<sub>2</sub>-β-Nal-D-Cys-3-I-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
133 H<sub>2</sub>-p-CN-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-p-CN-Phe-NH<sub>2</sub>;  
134 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-Dip-NH<sub>2</sub>;  
135 H<sub>2</sub>-β-Nal-D-Cys-Bta-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
136 H<sub>2</sub>-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
137 H<sub>2</sub>-Bpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Bpa-NH<sub>2</sub>;  
138 H<sub>2</sub>-Iph-D-Cys-Pal-D-Trp-Lys-Val-Cys-Iph-NH<sub>2</sub>;  
139 H<sub>2</sub>-Trp-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
140 H<sub>2</sub>-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
141 H<sub>2</sub>-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
142 H<sub>2</sub>-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-p-Cl-Phe-NH<sub>2</sub>;  
143 H<sub>2</sub>-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Cha-Cys-p-Cl-Phe-NH<sub>2</sub>;  
144 H<sub>2</sub>-p-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-p-Cl-Phe-  
145 NH<sub>2</sub>;

146           H<sub>2</sub>-p-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
147           H<sub>2</sub>-p-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
148           H<sub>2</sub>-p-F-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
149           H<sub>2</sub>-p-F-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Tle-Cys-β-Nal-NH<sub>2</sub>;  
150           H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
151           (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
152           H<sub>2</sub>-p-NO<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
153           (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;  
154           H<sub>2</sub>-p-NO<sub>2</sub>-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-β-  
155           Nal-NH<sub>2</sub>;  
156           (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-Phe-  
157           D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-β-Nal-NH<sub>2</sub>;  
158           (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-Phe-  
159           D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Tyr-NH<sub>2</sub>;  
160           H<sub>2</sub>-p-NO<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
161           (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-Phe-  
162           D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
163           (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-Phe-  
164           D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;  
165           H<sub>2</sub>-β-Nal-D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-β-Nal-  
166           NH<sub>2</sub>; or  
167           (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
168           Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH<sub>2</sub>; or  
169           a pharmaceutically acceptable salt thereof.

1           8.    A compound of claim 2, wherein A<sup>1</sup> is a D-aromatic  
2           amino acid.

1           9.    A compound of claim 8, wherein A<sup>1</sup> is D-β-Nal, D-  
2           o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-  
3           p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-  
4           m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-  
5           F<sub>5</sub>-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-  
6           Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; A<sup>3</sup> is β-Nal, o-X-Phe  
7           (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe

8 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe  
9 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe,  
10 Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or  
11 Pal; A<sup>6</sup> is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly,  
12 Nle,  $\beta$ -Ala, Gaba, or Val; and A<sup>8</sup> is the D- or L-isomer of Thr,  
13 Dip, F<sub>5</sub>-Phe, p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
14 CN, or NO<sub>2</sub>), o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
15 CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
16 CN, or NO<sub>2</sub>), Igl, Tyr(Bzl), or  $\beta$ -Nal.

1 10. A compound of claim 9, wherein A<sup>1</sup> is D- $\beta$ -Nal, D-  
2 Npa, D-Igl, D-Phe, D-p-F-Phe, D-Trp, D-p-Cl-Phe, or D-p-  
3 CN-Phe; A<sup>3</sup> is Tyr, Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or  
4 Leu; A<sup>8</sup> is p-F-Phe,  $\beta$ -Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-  
5 Phe; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or  
6 4-(2-hydroxyethyl)-1-piperazineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub>  
7 is NH<sub>2</sub>.

1 11. A compound of claim 10, wherein A<sup>3</sup> is Pal.

1 12. A compound of claim 8, of the formula:  
2 H<sub>2</sub>-D-Phe-D-Pen-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
3 H<sub>2</sub>-D- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;  
4 H<sub>2</sub>-D- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
5 H<sub>2</sub>-D- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
6 H<sub>2</sub>-D-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;  
7 H<sub>2</sub>-D-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>;  
8 H<sub>2</sub>-D- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>;  
9 H<sub>2</sub>-D- $\beta$ -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D- $\beta$ -Nal-NH<sub>2</sub>;  
10 H<sub>2</sub>-D-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-p-F-Phe-NH<sub>2</sub>;  
11 H<sub>2</sub>-D-Bip-D-Cys-Tyr-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
12 H<sub>2</sub>-D-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
13 H<sub>2</sub>-D-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys- $\beta$ -Nal-NH<sub>2</sub>;  
14 H<sub>2</sub>-D-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-p-Cl-Phe-NH<sub>2</sub>;

15 p-NO<sub>2</sub>-D-Phe-D-Cys-Pal-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-  
16 NH<sub>2</sub>;  
17 p-NO<sub>2</sub>-D-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Val-Cys-Tyr(Bzl)-  
18 NH<sub>2</sub>;  
19 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-D-  
20 Phe-D-Cys-Pal-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH<sub>2</sub>; or  
21 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-p-NO<sub>2</sub>-D-  
22 Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Val-Cys-Tyr(Bzl)-NH<sub>2</sub>; or  
23 a pharmaceutically acceptable salt thereof.

24 13. A compound of claim 2, wherein A<sup>1</sup> is deleted, R<sup>1</sup>  
25 is substituted or unsubstituted E<sub>1</sub>CO, and R<sub>2</sub> is H.

1 14. A compound of claim 13, wherein R<sub>1</sub> is substituted  
2 or unsubstituted E<sub>1</sub>CO (where E<sub>1</sub> is phenyl,  $\beta$ -naphthylmethyl,  $\beta$ -  
3 pyridinylmethyl, or 3-indolylmethyl); A<sup>3</sup> is  $\beta$ -Nal, o-X-Phe  
4 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe  
5 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe  
6 (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe,  
7 Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or  
8 Pal; A<sup>6</sup> is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly,  
9 Nle,  $\beta$ -Ala, Gaba, or Val; and A<sup>8</sup> is the D- or L-isomer of Thr,  
10 Dip, F<sub>5</sub>-Phe, p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
11 CN, or NO<sub>2</sub>), o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
12 CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>,  
13 CN, or NO<sub>2</sub>), Igl, Tyr(Bzl), or  $\beta$ -Nal.

1 15. A compound of claim 14, wherein R<sub>1</sub> is E<sub>1</sub>CO (where  
2 E<sub>1</sub> is 4-hydroxy-phenyl,  $\beta$ -naphthylmethyl, or phenyl); A<sup>3</sup> is  
3 Tyr, Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or Leu; A<sup>8</sup> is p-  
4 F-Phe,  $\beta$ -Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R<sub>3</sub> is NH<sub>2</sub>.

1 16. A compound of claim 15, wherein A<sup>3</sup> is Pal.

1 17. A compound of claim 14, of the formula

2 (H) (3-phenylpropionyl)-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-  
3 Nal-NH<sub>2</sub>;  
4 (H) (3-phenylpropionyl)-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-  
5 Nal-NH<sub>2</sub>;  
6 (H) (3-phenylpropionyl)-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-  
7 Nal-NH<sub>2</sub>;  
8 (H) (3-phenylpropionyl)-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-  
9 Nal-NH<sub>2</sub>;  
10 (H) (3-phenylpropionyl)-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-  
11 NH<sub>2</sub>;  
12 (H) (3-phenylpropionyl)-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-  
13 NH<sub>2</sub>;  
14 (H) (3-phenylpropionyl)-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-  
15 NH<sub>2</sub>;  
16 (H) (3-phenylpropionyl)-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-  
17 NH<sub>2</sub>;  
18 (H) (3-[2-naphthyl]propionyl)-D-Cys-Tyr-D-Trp-Lys-Val-  
19 Cys-β-Nal-NH<sub>2</sub>;  
20 (H) (3-[2-naphthyl]propionyl)-D-Cys-Pal-D-Trp-Lys-Val-  
21 Cys-β-Nal-NH<sub>2</sub>;  
22 (H) (3-[2-naphthyl]propionyl)-D-Cys-Tyr-D-Trp-Lys-Thr-  
23 Cys-β-Nal-NH<sub>2</sub>;  
24 (H) (3-[2-naphthyl]propionyl)-D-Cys-Pal-D-Trp-Lys-Thr-  
25 Cys-β-Nal-NH<sub>2</sub>;  
26 (H) (3-[2-naphthyl]propionyl)-D-Cys-Tyr-D-Trp-Lys-Val-  
27 Cys-Thr-NH<sub>2</sub>;  
28 (H) (3-[2-naphthyl]propionyl)-D-Cys-Pal-D-Trp-Lys-Val-  
29 Cys-Thr-NH<sub>2</sub>;  
30 (H) (3-[2-naphthyl]propionyl)-D-Cys-Tyr-D-Trp-Lys-Thr-  
31 Cys-Thr-NH<sub>2</sub>;  
32 (H) (3-[2-naphthyl]propionyl)-D-Cys-Pal-D-Trp-Lys-Thr-  
33 Cys-Thr-NH<sub>2</sub>;  
34 (H) (3-[p-hydroxyphenyl])-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-  
35 Nal-NH<sub>2</sub>;

36 (H) (3-naphthylpropionyl)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-  
37  $\beta$ -Nal-NH<sub>2</sub>;  
38 (H) (3-naphthylpropionyl)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-  
39 Thr-NH<sub>2</sub>;  
40 (H) (3-phenylpropionyl)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys- $\beta$ -  
41 Nal-NH<sub>2</sub>; or  
42 (H) (3-phenylpropionyl)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-  
43 Thr-NH<sub>2</sub>; or  
44 a pharmaceutically acceptable salt thereof.

1 18. A compound of claim 2, wherein R<sub>3</sub>, together with  
2 the carbonyl group of A<sup>8</sup> attached thereto, are reduced to form  
3 H, lower alkyl, or hydroxy lower alkyl.

1 19. A compound of claim 18, wherein A<sup>1</sup> is the D- or L-  
2 isomer of  $\beta$ -Nal, o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>,  
3 NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>,  
4 NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>,  
5 NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl,  
6 Tyr(I), Bta, Bip, Npa, or Pal; A<sup>3</sup> is  $\beta$ -Nal, o-X-Phe (where X  
7 is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is  
8 H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H,  
9 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal,  
10 Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A<sup>6</sup> is Thr,  
11 Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle,  $\beta$ -Ala, Gaba,  
12 or Val; and A<sup>8</sup> is the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, p-X-  
13 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), o-X-  
14 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-  
15 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), Igl,  
16 Tyr(Bzl), or  $\beta$ -Nal.

1 20. A compound of claim 19, wherein A<sup>1</sup> is the D- or  
2 L-isomer of  $\beta$ -Nal, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN-Phe;  
3 A<sup>3</sup> is Tyr, Tyr(I), or Pal; A<sup>6</sup> is Val, Tle, Nle, Ile, or Leu; A<sup>8</sup>  
4 is p-F-Phe,  $\beta$ -Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R<sub>1</sub> is

5 H,  $\text{CH}_3\text{CO}$ , 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-  
6 hydroxyethyl)-1-piperizineethanesulfonyl;  $R_2$  is H, and  $R_3$ ,  
7 together with the carboxy group of  $A^8$  attached thereto, are  
8 reduced to form H or  $\text{CH}_3\text{OH}$ .

1 21. A compound of claim 20, wherein  $A^3$  is Pal.

1 22. A compound of claim 19, of the formula:

2  $\text{H}_2\text{-}\beta\text{-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-}$   
3 hydroxymethyl)-3-hydroxy)propylamide;  
4  $(\text{H})(\text{CH}_3\text{CO})\text{-}\beta\text{-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-}$   
5 hydroxymethyl)-3-hydroxy)propylamide;  
6  $(\text{H})(4\text{-(2-hydroxyethyl)-1-piperazinylacetyl})\text{-}\beta\text{-Nal-D-}$   
7 Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-hydroxymethyl)-3-  
8 hydroxy)propylamide;

9  $(\text{H})(4\text{-(2-hydroxyethyl)-1-piperizineethanesulfonyl})\text{-}\beta\text{-}$   
10 Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-hydroxymethyl)-3-  
11 hydroxy)propylamide;

12  $\text{H}_2\text{-}\beta\text{-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-}$   
13 hydroxymethyl)-3-hydroxy)propylamide;

14  $(\text{H})(\text{CH}_3\text{CO})\text{-}\beta\text{-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-}$   
15 hydroxymethyl)-3-hydroxy)propylamide;  
16  $(\text{H})(4\text{-(2-hydroxyethyl)-1-piperazinylacetyl})\text{-}\beta\text{-Nal-D-}$   
17 Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-hydroxymethyl)-3-  
18 hydroxy)propylamide;

19  $(\text{H})(4\text{-(2-hydroxyethyl)-1-piperizineethanesulfonyl})\text{-}\beta\text{-}$   
20 Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-hydroxymethyl)-3-  
21 hydroxy)propylamide;

22  $\text{H}_2\text{-}\beta\text{-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-}$   
23 hydroxymethyl)-3-hydroxy)propylamide;

24  $(\text{H})(\text{CH}_3\text{CO})\text{-}\beta\text{-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-}$   
25 hydroxymethyl)-3-hydroxy)propylamide;

26  $(\text{H})(4\text{-(2-hydroxyethyl)-1-piperazinylacetyl})\text{-}\beta\text{-Nal-D-}$   
27 Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-hydroxymethyl)-3-  
28 hydroxy)propylamide;

29 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - $\beta$ -  
30 Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R- (2-hydroxymethyl) -3-  
31 hydroxy) propylamide;  
32 H<sub>2</sub>- $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R- (2-  
33 hydroxymethyl) -3-hydroxy) propylamide;  
34 (H) (CH<sub>3</sub>CO) - $\beta$ -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R- (2-  
35 hydroxymethyl) -3-hydroxy) propylamide;  
36 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) - $\beta$ -Nal-D-  
37 Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R- (2-hydroxymethyl) -3-  
38 hydroxy) propylamide;  
39 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) - $\beta$ -  
40 Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R- (2-hydroxymethyl) -3-  
41 hydroxy) propylamide;  
42 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R- (2-  
43 hydroxymethyl) -3-hydroxy) propylamide;  
44 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R- (2-  
45 hydroxymethyl) -3-hydroxy) propylamide;  
46 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
47 Tyr-D-Trp-Lys-Val-Cys-2R,3R- (2-hydroxymethyl) -3-  
48 hydroxy) propylamide;  
49 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
50 D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R- (2-hydroxymethyl) -3-  
51 hydroxy) propylamide;  
52 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R- (2-  
53 hydroxymethyl) -3-hydroxy) propylamide;  
54 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R- (2-  
55 hydroxymethyl) -3-hydroxy) propylamide;  
56 (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) Phe-D-Cys-  
57 Pal-D-Trp-Lys-Val-Cys-2R,3R- (2-hydroxymethyl) -3-  
58 hydroxy) propylamide;  
59 (H) (4- (2-hydroxyethyl) -1-piperizineethanesulfonyl) Phe-  
60 D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R- (2-hydroxymethyl) -3-  
61 hydroxy) propylamide;  
62 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R- (2-  
63 hydroxymethyl) -3-hydroxy) propylamide;

64 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-  
65 hydroxymethyl)-3-hydroxy)propylamide;  
66 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-  
67 Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-hydroxymethyl)-3-  
68 hydroxy)propylamide;  
69 (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl) Phe-  
70 D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-hydroxymethyl)-3-  
71 hydroxy)propylamide;  
72 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-  
73 hydroxymethyl)-3-hydroxy)propylamide;  
74 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-  
75 hydroxymethyl)-3-hydroxy)propylamide;  
76 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-  
77 Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-hydroxymethyl)-3-  
78 hydroxy)propylamide;  
79 (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl) Phe-  
80 D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-hydroxymethyl)-3-  
81 hydroxy)propylamide;  
82 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-  
83 naphthyl)ethylamide;  
84 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-  
85 naphthyl)ethylamide;  
86 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
87 Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
88 (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
89 Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
90 H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-  
91 naphthyl)ethylamide;  
92 (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-  
93 naphthyl)ethylamide;  
94 (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
95 Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
96 (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
97 Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

98                   H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)  
99    ethylamide;  
100                  (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-  
101    naphthyl)ethylamide;  
102                  (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
103    Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;  
104                  (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
105    Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;  
106                  H<sub>2</sub>-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-  
107    naphthyl)ethylamide;  
108                  (H) (CH<sub>3</sub>CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-  
109    naphthyl)ethylamide;  
110                  (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
111    Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;  
112                  (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
113    Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;  
114                  H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-  
115    naphthyl)ethylamide;  
116                  (H) (CH<sub>3</sub>CO)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-  
117    naphthyl)ethylamide;  
118                  (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-  
119    Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
120                  (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)Phe-  
121    D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
122                  H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)  
123    ethylamide;  
124                  (H) (CH<sub>3</sub>CO)Phe-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-  
125    naphthyl)ethylamide;  
126                  (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-  
127    Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
128                  (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)Phe-  
129    D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;  
130                  H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)  
131    ethylamide;

132 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-  
133 naphthyl)ethylamide;  
134 (H) (4- (2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-  
135 Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl)ethylamide;  
136 (H) (4- (2-hydroxyethyl)-1-piperazineethanesulfonyl) Phe-  
137 D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl)ethylamide;  
138 H<sub>2</sub>-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-  
139 naphthyl)ethylamide;  
140 (H) (CH<sub>3</sub>CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-  
141 naphthyl)ethylamide;  
142 (H) (4- (2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-  
143 Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl)ethylamide;  
144 (H) (4- (2-hydroxyethyl)-1-piperazineethanesulfonyl) Phe-  
145 D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl)ethylamide;  
146 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R- (2-  
147 naphthyl)ethylamide;  
148 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R- (2-  
149 naphthyl)ethylamide;  
150 H<sub>2</sub>-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R, 3R- (2-  
151 hydroxymethyl)-3-hydroxy)propylamide; or  
152 H<sub>2</sub>-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R, 3R- (2-  
153 hydroxymethyl)-3-hydroxy)propylamide; or  
154 a pharmaceutically acceptable salt thereof.

1 23. A compound of claim 1, wherein A<sup>2</sup> is a D-aromatic  
2 amino acid or a D-aliphatic amino acid, A<sup>7</sup> is an aromatic  
3 amino acid or an aliphatic amino acid, and A<sup>4</sup> is D-Trp.

1 24. A compound of claim 23, wherein A<sup>1</sup> is an L- amino  
2 acid and A<sup>2</sup> is a D-aromatic amino acid.

1 25. A compound of claim 24, wherein A<sup>1</sup>, A<sup>3</sup>, and A<sup>7</sup>  
2 independently, is β-Nal, o-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
3 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), p-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,  
4 OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H, OH, CH<sub>3</sub>, halo,

5      OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His,  
6      Igl, Tyr(I), Bta, Bip, Npa, or Pal; A<sup>2</sup> is D- $\beta$ -Nal, D- $\alpha$ -X-Phe  
7      (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-p-X-Phe  
8      (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-m-X-Phe  
9      (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-F<sub>5</sub>-Phe,  
10     D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-  
11     Bta, D-Bip, D-Npa, or D-Pal; A<sup>6</sup> is Thr, Ser, Tle, Thr(Bzl),  
12     Abu, Ala, Ile, Leu, Gly, Nle,  $\beta$ -Ala, Gaba, or Val; and A<sup>8</sup> is  
13     the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, p-X-Phe (where X is H,  
14     OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>),  $\alpha$ -X-Phe (where X is H,  
15     OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), m-X-Phe (where X is H,  
16     OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), Igl, Tyr(Bzl), or  $\beta$ -Nal.

1            26. A compound of claim 25, wherein A<sup>1</sup> is  $\beta$ -Nal or  
2      Phe, A<sup>2</sup> is D-Cpa or D-Phe; A<sup>3</sup> is Phe or Tyr; A<sup>6</sup> is Abu, Thr, or  
3      Val; A<sup>7</sup> is Phe; and A<sup>8</sup> is Thr; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-  
4      hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-  
5      piperazineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub> is NH<sub>2</sub>.

1       27. A compound of claim 25 of the formula:  
2       H<sub>2</sub>-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
3       H<sub>2</sub>-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
4       H<sub>2</sub>-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
5       H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
6       (H) (CH<sub>3</sub>CO)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
7       (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
8       Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
9       (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
10      Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
11      H<sub>2</sub>-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
12      (H) (CH<sub>3</sub>CO)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
13      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
14      Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
15      (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
16      Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
17      H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
18      (H) (CH<sub>3</sub>CO)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
19      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
20      Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
21      (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
22      Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
23      H<sub>2</sub>-β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
24      (H) (CH<sub>3</sub>CO)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
25      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
26      Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
27      (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
28      Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
29      H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;  
30      (H) (CH<sub>3</sub>CO)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;  
31      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-  
32      Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>; or  
33      (H) (4-(2-hydroxyethyl)-1-piperazineethanesulfonyl)-β-  
34      Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>;  
35      H<sub>2</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>; or

36 H<sub>1</sub>-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>; or  
37 a pharmaceutically acceptable salt thereof.

1                   28. A compound of claim 23, wherein A<sup>1</sup> is a D-amino  
2 acid and A<sup>2</sup> is a D-aromatic amino acid.

1           29. A compound of claim 28, wherein A<sup>1</sup> and A<sup>2</sup>,  
2 independently, is D-β-Nal, D-*o*-X-Phe (where X is H, OH, CH<sub>3</sub>,  
3 halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-*p*-X-Phe (where X is H, OH, CH<sub>3</sub>,  
4 halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-*m*-X-Phe (where X is H, OH, CH<sub>3</sub>,  
5 halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), D-F<sub>5</sub>-Phe, D-Trp, D-Dip, D-2-Pal,  
6 D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-  
7 Pal; A<sup>3</sup> and A<sup>7</sup>, independently, is β-Nal, *o*-X-Phe (where X is H,  
8 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), *p*-X-Phe (where X is H,  
9 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), *m*-X-Phe (where X is H,  
10 OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), F<sub>5</sub>-Phe, Trp, Dip, 2-Pal,  
11 His, Igl, Tyr(I), Bta, Bip, Npa, Tyr(Bzl), or Pal; A<sup>6</sup> is Thr,  
12 Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, β-Ala, Gaba,  
13 or Val; and A<sup>8</sup> is the D- or L-isomer of Thr, Dip, F<sub>5</sub>-Phe, *p*-X-  
14 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), *o*-X-  
15 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), *m*-X-  
16 Phe (where X is H, OH, CH<sub>3</sub>, halo, OCH<sub>3</sub>, NH<sub>2</sub>, CN, or NO<sub>2</sub>), Igl,  
17 Tyr(Bzl), or β-Nal.

1                   30. A compound of claim 29, wherein A<sup>1</sup> is D-β-Nal or  
2 D-Phe; A<sup>2</sup> is D-Cpa or D-Phe; A<sup>3</sup> is Phe or Tyr; A<sup>6</sup> is Thr or  
3 Val; A<sup>7</sup> is Phe; and A<sup>8</sup> is Thr; R<sub>1</sub> is H, CH<sub>3</sub>CO, 4-(2-  
4 hydroxyethyl) -1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-  
5 piperazineethanesulfonyl; R<sub>2</sub> is H; and R<sub>3</sub> is NH<sub>2</sub>.

1       31. A compound of claim 29 of the formula:  
2       H<sub>2</sub>-D-β-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
3       H<sub>2</sub>-D-β-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>;  
4       H<sub>2</sub>-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>;  
5       H<sub>2</sub>-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH<sub>2</sub>; or  
6       H<sub>2</sub>-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH<sub>2</sub>; or  
7       a pharmaceutically acceptable salt thereof.